MRKR - Earnings call transcript Q4 2017 | Marker Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day everyone and welcome to the TapImmune Fourth Quarter and Full Year 2017 Corporate Update Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions and please note today’s event is being recorded. I would now like to turn the conference over to Josh Drumm. Please go ahead.

Josh Drumm

you. Thank welcome conference fourth call. and end and the investor XXXX to afternoon quarter TapImmune’s year Good

forward-looking Before I make concerning would the like turning call to the over following to management, statements. remarks

make of of cancer forward-looking the forth the its management’s historical Any prospects any fact Company’s Securities Private technology, statements including we clinical vaccine the to candidates, future beliefs, During [Audio about limited the its statements regarding in advancement Gap] call, of Litigation the position, costs of the plans and financial meaning Company’s within goals projected product other set and PolyStart will following. than expectations, acceptance studies future its and candidates. for revenues market statements

and or commercial the cost for development as candidates to and anticipated product statements business to the costs. thereof, projections future transactions, results Company’s regulatory the the timing position, product projections statements market include other timing development Forward-looking expectations, manufacturing any expectations component to any and and licensing about spending cash our and nature our expectations and as as and plans, possible action, and of product clinical plans

Commission or in forward-looking required should undue Please by XX, as as TapImmune these in factors the as reliance may filings may to note regulatory a these XX-K due from investors actually differ variety the commercialization. forward-looking TapImmune's except Securities well results the These annual described not not including and Exchange not uncertainties approvals Company’s XXXX, SEC’s to at these goals in TapImmune but projections March estimates on statements which detail intend of with described or actual not update Our related greater materially to tapimmune.com, development, and does report important including law. place statements. on limited filed, to these clinical website. achieve are and that statements Form risks the available is plans

Dr. be Mr. Officer turn At Chief time, Peter TapImmune; Executive Financial Kenney, will Officer of call President Peter the Peter, Chief Richard of on us Loiacono, to Dr. Mr. it Executive please TapImmune. my over and to and go call and Officer. Hoang, today pleasure Joining Michael President Chief Officer; ahead. Hoang, now Medical is this Chief

Peter Hoang

studies. Thank building joining my you. and terms thanks Good to and the that non-dilutive call cancer today. TapImmune this for clinical additional has our It's to data through afternoon update of pleasure clinical values publication us programs funding advancing progress and in vaccine made our host highlight for

update, Kenney, for the Chief to Richard Before over Officer, I hand a Medical go our some Dr. company call clinical let recent me highlights.

intended was reaching of recently and have patients the alpha, multi-epitope that a Phase had X without against we receptor to like oncology milestones. well are our published multiple immune not These responses shows the designed fantastic goals type. quarterly to advances call, vaccine first in women years last quarter. during we reported towards What’s that with although mechanism XX% developed a responses remission based with the folate and tolerated cancer. efficacy targeting for say durable of reviewed promising HLA progression robust least significant with outcomes, of data epitopes. announced cancer against ovarian immunity our survival achieving of follow-up trial the follow-up safety we T-cell think initial clinical our I’d potential TPIVXXX. data is I antigen publication the at encouraging immunization evaluate more very two journal vaccination Since cancer last their and of for was breast all in alpha even all, of made absolutely vaccinated specific initiation action ovarian TPIVXXX, immune progress an and free patients subset demonstrate clear receptor study over trial alpha following leading on developed have at alive the We This remained in TPIVXXX aligns anti-tumor of results that That receptor folate regard clinical benefit proof-of-concept lasting vaccine. and period. large clinical First patients our folate from the by and a evidence to patients majority All in a research for and the of during and peer lasting

have who and median an And compares achieve free operations. where we clinical survival of women year, schedule that progression of This a women patient ongoing in as this half setting does population not first certainly statistical value TPIV study progression were sponsored TapImmune of setting full a see to a rise patients of Last could have clear free expect larger in our to improve X for our stage study negative of of TapImmune when months receiving for track the to the the the the significance, expect days highlights almost same and which Phase it the had prolonged our our study This the free that by vaccine. the XX of which we only currently result similar Phase well the on XXX of days. two XXX X was from well and approval gone very data analysis may chemotherapy we surgery favorably Enrollment patients ahead concerted vaccine clinical effective enrolled. randomized remission healthy Should is in standard still a potential breast trend dosing care effort double-blind survival indication. achieve very level patients efficiency immune pleased through towards milestone cancer -- conduct multi-epitope its intriguing respond progression this systems an to survival While effective controlled vaccine and of enrollment where to received in TPIVXXX as triple investigators. the interim in would of to first collected for patients we the median to our may data is first in believe have viable observed of potentially well. historical we results X our at remains have Phase disease, enrolling pathway mid-XXXX, in

fact, patients contributing to [indiscernible] diligence were quarters and the able development I'd to milestone two In XX months of their in and the we to all accomplish of versus teams our the quarters this patients for two the XXXX. for investigators as our as vaccine. first [Audio of like thank this well last X.X their Gap] XXXX through

year triple the XXX had Clinic first the trial first the that Mayo Phase in of X cancer completed we cancer for patient our vaccinated of breast in who women addition, last prevention negative and advanced chemotherapy. their In line late surgery radiotherapy with recurrence patient announced or TPIVXXX

study a the reminder, $XX.X from million is Defense. this Department efficacy fully grant a large funded of U.S. by As

will vaccination While cost complete, a all to prevent patient some TapImmune. us it to of cancer the demonstrate opportunity direct potential to recurrence to the study take in tremendous essentially TPIVXXX incurring time the represents a no for large while population,

combination is the of expressed positive the Clinic, Mayo previously Herceptin supplant there particularly the our the I seen study statistically Herceptin. fact, peptides in another In fourth X results Phase in cancer Pharma study with new to single vaccine a single results quarter this patients. X/X degree with using in five would planned of recent five I funding by was in TPIVXXX potential the vaccine, combination indication. embedded same fully with one evaluate that know their TPIVXXX, product. our yet the shares Department high am our by study HERXneu interest Phase of HERX conjunction peptide significant Defense immunology Sellas NeuVax in encouraged for with smaller breast peptide HERX clinical peptide in In

so TPIVXXX. very I believe And well bodes this for

very Given peptide that the for multi-peptide drive that maybe is NeuVax to results approach able I’m even upon build better optimistic TPIVXXX single patients. and our approach,

types X optimistic happy the are has Phase to our be The would deferred in program a taking this fully interest pleased larger in trial Department where by PolyStart non-dilutive larger allowed discussions study of to discussions or these for successful. clinical capital We of We look Defense pleased strong from it vaccine of Defense. that complete U.S. be a comprising would our which last office as favorable enhancement are is TPIVXXX. to Department the full expands novel coverage would TapImmune ready Department arrays obviously from PAAs. the study poly-antigen Defense. be and if that Mayo so intellectual of In funding peptide and with funded study essentially I’m extremely to application a that half patent such Clinic, U.S. significant of be improve It property pipeline, ongoing funding receive pipeline Should sequences technology. the addition our quarter, different DoD reasonably Trade the our Patent and the may the of for updating in very when of outcome the to begin; and announce you

portion. other The what previously new until any of this is work our or our new that parties antigen HERXneu us PPAs targets XXXX. acid-based patent absence, vaccines our to driver proprietary or While, receptor develop portions allowing to the for outside pathogen nucleic PolyStart tumor already polypeptide patents broadens folate directly target a any substantial believe candidates. epitopes, exclusivity of significant to PPA value to molecular value or In TapImmune. commercial adds vaccine issue freedom alpha peptide covers composite any covered this to to new current with with ability replay future allowance We

a enhance leverage that over through this Kenney, proof-of-concept pre-clinical I drive in Moreover, demonstrate Dr. to have shareholder opportunity the we PolyStart, turn to continue we I to we believe important position value to opportunities. to strategic be expect As asset. for it before

Given report some significant and my approve believe immediately it strategic be I pleased to continue to we we view in have a advance and clinical to these to opportunity provide the on immuno-oncology, greater advance Medical value. I’m strategic opportunities hand landscape to the our opportunities we’ll strategic that call that initiatives have that, to to that I’ll and very discussions significantly to the have shareholder on can chance of this our Rick? With Chief Officer Kenney, programs. near-term. execute hopeful detail I’m Rick that

Dr. Richard Kenney

lot Peter. a Thanks

and will touchy, try what little happen. I I lines to phone Just being my a to -- this see so know, get through we’ll will

event XX% showed over XX% the type ovarian, months. study six with the then Study period Analysis response months' by vaccination to initial course X vaccine following group. include strong TPIVXXX that to was tolerated cancer Phase patients evaluate which candidates our result. with alpha, was XX without response clinical long grade lung generated kind safety and adverse tumor targeting was months. mentioned which multiple vaccination, TPIVXXX is TPIVXXX. HLA for the expressed T-cell to those recently and responses responding responses epitodes our the cyclophosphamide in associated expect only immunization cancer in The a multi-epitope of immunity immunized is lasting was vaccine had and the type one of folate maximum earlier, breast long-term pre-treatment that ovarian lead clinical local research designed or vaccine the immune an five medium general. over slowly a of results of following Generation trial for TPIVXXX. X immune is published protein immunity with a of patients breast T-cell and Peter in TPIVXXX receptor over patients membrane As cancers. and related alternation were patient demonstrated and the and an Patients robust monitored well additional of peptide antigen-specific all developed

of specifically and disease presence receptor hope proof to for high specific achieve memory expected a was that we long responses alpha receptor antigen period. fully to immune to responses T-cells vaccine of time demonstrate could we multi-epitode to post be shown These with the and at solid immunization As sustained lasting against in to these levels of immunities immunity clinical improve, longer achieve vaccine, therapeutic approach the a throughout principle XX-months T-cell peptide The suggest outcome the the the folate remaining progression. patients. with translate durable the monitoring

XXX large mentioned, Despite the patients wide small confidence the cancer the the observed Medicine study ovarian days with Phase of of to days In a emission trial these X that results the of time is this back in conducted they with to New clinical quite XXX of which bevacizumab, their progression XXX favorably of vaccine. from control which The XXXX. a interval as received number PFS Finally that were in had patients, in had entered a controlled published treatment cancer Journal patients and at of XXX of was ICONX days. interval, medium marketed confident contributes the study patient England first there Peter data the standard compared results the XX% study, in population before time the median study as care free who largest of survival recurring. XXX

by Our medium much is PFS comparison. to longer XXX days

much While better randomized, if ongoing the multi-parallel speaks this website believe impact helpful X be currently this in not cancer data analysis the improved PFS you chemotherapy was and X.XXX on will might that of includes PFS our times clinical that understand X X ovarian first women very historical interval. the the Phase number of using is this were cancer prolonged for Phase still enrolling TPIVXXX I of is and To following treatment. the our data we outcomes our understanding study insight year. produce our the download hypothetical contrast in in the sugary XX X days and our for fact, PFS in X strong potential we're began on patients. confidence we potential summarizes look paper people XXX encourage on to patients the of look PFS from the a our and We of remission remission. the in white of August initial X Phase last in XX study references. patient, data at number findings of patients study particularly clinical ovarian in Phase very population. at the Based This this in by analysis, to ran available potential simulation is XX% Clearly patient first our like, in distribution Phase patient simulated of light TPIVXXX at to which that and meaningful what statistical the larger our on where median with our we figures for simulation results, encouraged certainly their additional Phase is study

the we patient lack data of previous of X hope a our as option and efficiently based to the remained of the saw from potential study Given PFS analysis focuses improvement as on once is as first and statistically achieved track currently patients our in Peter-mentioned, protocol enroll study, this Phase to population significant possible in demonstrating treatment interim PFS. continuing a available conduct in in our benefit half we blinded on enrollment early XXXX, on the data. We're

these of study vaccine as ovarian the analysis was by stage cancer. poor we in combination inhibitor antagonist completed at arm investigators the the MSKCC. typically and currently PD-LX two very this inhibitor results approved have women XX XXXX, study’s a TPIVXXX We option. peptide in cancer is TapImmune-sponsored very TPIVXXX no are with they being checkpoint study on negative enrolled interim also women still platinum are the the the cancer is failed single patients. Enrollment discussion released In studying as based in in were required phase with first Kettering anticipate planned a AstraZeneca's the and survival Women clinical soon with suspended advanced design, FDA resistant enrollment Sloan a this data center a triple final platinum while completed the conducted. to study treatment, X prior have their X analyzed patients reporting also we as least in breast who and Based treatment by recurrent to ovarian was This use is with by one or the at Memorial checkpoint first case, and prognosis with durvalumab. Phase therapy. conducted persistent the being In cancer

TNBC. are completed the to maintenance that of study We immune will that enrollment two with X women ahead study this is and regimen phase vaccine in The November. months study dose was the can determine itself schedule Phase in announce randomized ongoing. of multicenter pleased optimal the antitumor help responses maximize This

negative in We reporting for analysis with TPIVXXX interim of responses will patient hospital by are the quarter third type also demonstrate Mayo's million collaborators by TPIVXXX, well this ovarian responses the year. varying breast treated expect in disease the currently The cancer, from of doses top the remission triple patients as disease trial women of by analyzing them the and patient XXX multiple the TPIVXXX with and being is prolonging generated breast without advanced we designed mentioned randomized, of is begin grant fourth was that studies first to and and Peter is characterizing efficacy from anticipate controlled cancer. funded preliminary patients. vaccination women completely Department line attempt negative triple fourth double-blind, the at that free the as time are which we or with correlate following the to interim our in quarter, progression study Between vaccine Defense, first immune our focus is of also line. will in these placebo of on prolonged breast done their in in survival receptor results data cancer safety immune anti-folate in Mayo This and $XX.X and clinic. dosed to with TPIVXXX in and patients

peptide forward this XB/XA Our breast successful be BOD about breast a about setting already is that positioned completed cancers to cancer excited and different in to added we and further vaccine. Phase very vaccine each standard launch grant stage Phase studying one breast in the has DCIS to cancer is Mayo in effective funding program fourth indication an We Mayo surgery in DCIS breast well, are that situ study and the complement carcinoma ductal secured our from X year look study targets or of chemotherapy in program underscores women cancer. breast TapImmune successful, and vaccine U.S. as new for settings. accounts second of clinical The a cancer. has Clinic early a proposition in since fifth HERXneu for HERX one day our is to chemotherapies. an exciting the with vaccine cancer breast could which and potential

DoD our the expand by We addition, with targeted discussions enable in time study timing vaccine an as soon our providing we to as Phase Clinic. that with this In to HERXneu forward cancers DoD, X also by this is while candidate, of driven vaccine look HERX are may the enrollment of Mayo our the begins. types of us update in the combination mentioned study patient Peter funding ongoing and Mayo for also regarding Herceptin. grant

you recall to five and initially in cancer. TapImmune peptide women clinical HERX submit for might As begin planned X/X vaccine HERX TPIVXXX, FDA to low Phase a called breast filing our study with

If cancer. able discussions it study positive ongoing fourth quarter fully TapImmune the in clinical to trastuzumab study altogether. in as for combination fruitful study, interest these initially sponsored DoD planned TPIVXXX Herceptin X Phase new prove a However, HERX would funding expressed X/X breast Phase we’re uses X new our then Phase that in secure larger the in and with funding U.S. replace

larger are peptide date While not largest of final the our study vaccine yet details could our that for that to we candidate. be study expect it

the secured as forward is We’re potential to study and providing protocol the funding updates finalized. looking the is on study

us well other expressed the direct development to shows of activity we opens has for through continued highlighted poly-antigen cells, the efficiently tenfold to of expands to the through and can in laboratory vaccine encode are at up In pipeline Peter greater In enabling enhance door on additional further more immune PolyStart call This that that PAA. target that use, to we T-cell. type surfacing advance proprietary our strategic internal cytotoxic expression coverage PolyStart the TapImmune, vaccine technology them both antigen been platform presented developers. antigens peptides the as and start the our able arrays pipeline, quantity of something patent generate that Peter to value the we’ve as the outline molecular studies, significantly for or the mentioned. as in can to addition The our to

partners a with developing infectious target to the vaccine additional Loiacono continue Thank call that, XXXX potential who As disease the over intellectual wider to based studies the be validate of might platform their able update with and or array property an this to you. oncology now outlining acid for of and interested of demonstrate PolyStart expect we to covering we financials. in I'll vaccine. to potency be all the our existing now Michael nucleic on With our turn enhancing CFO, value

Dr. Michael Loiacono

pleased am to XXXX. for review Thanks, Rick. financials our I

net Firstly contained encourage filed indicated of in as information footnotes and our the of results financial we’ve Josh our approximately the results our read to share diluted loss explanation fiscal loss loss or for basic and million or March for was to our for XXXX, and on more to $X.XX XX-K financial net for you report XXXX we XX-K share XXrd, $X.XX million, respect $X.XX With per and X.X per Drumm XX XXXX. statements. compared a complete our

expenses referenced, As impacted gain Operating XX.X compared for warrant $X.X by a an million, value R&D positively were to XX%. were for million the change XXXX X.X for X.X expenses in in with liabilities. fair loss XXXX in trials. X.X expense to million million million stock-based million XXXX, G&A of in year as expenses. increase compared during from net XXXX. X.X X.X G&A due year-over-year Phase a compensation to of to mainly expenses clinical spending related million XXXX. non-cash increase was increased increased This X increased to the The increased million was attributable our in substantial was for $X.X year

was million operations with in compared used the provided of year $X.X million, cash Our cash in X.X financing to by for prior XXXX approximately $X.X the activities.

year decreasing for X.X cash the million. was net Our

X.X of quarter We fourth XXXX, XXXX for with we For of used the X.X approximately operations. cash million. ended million cash of

rate of quarterly XXXX. we to quarter, cash fourth we sufficient of believe to get QX out cash have a the As similar burn into

closing need remarks. be call that believe now the go hand will additional cash and I we forward. will available We Peter? as financing for back to also for Peter

Peter Hoang

efficient remain studies planned. of only funded allows Of by clinical milestone six clinical clinical cancer grants by very stage these we’re and advance to internal a us the to pipeline return to trajectory, multiple their underserved to programs that In fully deep the Michael. indications. for in ways I Half ongoing two to other We clinical catalysts programs sponsored shareholders efforts. Mayo of believe I forward. investment. were pipeline a Thanks, leading X moving trial immuno-oncology be with forward successful expected company a can lead argue would significantly parallel studies significant the and clinical through This with to hope pipeline. trials and our I in our our continues Clinic strongest two active given other to size Mayo debt immuno-oncology is we execution our of TapImmune. undervalued the for remain several the capital exploring significant candidates support company that that vaccine our a that stage our U.S. progress cancer matter no Department Company on great TapImmune to of Defense in continued of expect Phase vaccine burst and going believe for giving Clinic. continuing four large will a be potential coming with on conclusion, I

I We continuing As validate to allows continued over exciting it to value programs. questions. may I’d attracting quarterly driver significant strategic to the can it Operator, for monetize line any we’re mature, also clinical thank our want our our this you forward like time, Company. open continues this that intellectual and Thanks to believe our continuing partnerships. towards look and the to platform in for milestones development to turn that questions your proprietary to on you through call our At us technology the that become a property execute have. pursuing I for the may to for for PolyStart team support. it to next shareholders effectively

Operator

now And ahead. Thank be [Operator WBB. with today the you, go first question session. we our will sir. Instructions] Brozak question-and-answer And Steve Please begin will

Steve Brozak

what already, it funding. them Do with of to And business us they and to are your you? a looking able work which a there result, patient probably tell you actually but non-diluted team company to when there over follow some clinicians, you up would biotech seems well. in you're see And different Can that need and And like they're and as model, with implications. call and I've about you on advocating with of the go got leverage and singularly we’re coming feedback? tried would component interest out of a important to looking give participation typically they or Can because dealing is you. the to trials clinician what question that this they the component us kind as types

Peter Hoang

call joining in appreciate absolutely, Yes, Steve. Thanks for the today. We your support.

are who for Because back nothing from clinicians these of likelihood trial among posted triple itself ever three So in our that of to our much is I'll that's that, ovarian me tell them. for to attention. has note have I'll approved continues what negative garnered programs was University therapy patient blog very She wait. for a all potential a vaccine are There the do through therapy. mouth receiving continue within there ways really lot Medical word right nice gathered disease tell think what And you since ever is patients this more Maryland our there But clinicians at the the to breast point. women our is first cancer over remission therapy the because It currently that coming the population HER in you patients -- getting this of is enthusiasm this and how ago Center, Phase X was as and striking years therapies. many now, know cancer in in population. received probably can interim you of I that today, vaccines no as know, we're all is their that year. of is steam, the more A who that patient a

of will striking in which the down and us, so that help you a what leading the after the enrollment shortly physicians. Company the a national two we And away in to clinical some design is challenge year, to help was time days we joined me And with in know take country I Dallas. conference always I trial is tell was discuss Come you for that had Dallas physicians investigator these this of wanted to had trails. for ovarian last clinic, October these patient as from to for

lot enrolled the at sites we're Kettering have three among of two seeing I've -- particularly of the way and been Sarah for Cannon, that enrolling Sloan clinician women I tell is I that and that and national terms alternative. So and sites otherwise really that XX very Memorial enthusiastic I that significant enthusiasm. I coverage the we're trial Mayo pleased that of and you're heard of two we've a these therapeutic characterize I And trial I site. with really to is trial think we've in in. the to me. important, that But lot in TPIV across sites. a would of in sites point of I'll no believe that tell those that clinical There reflected here have who about seems cancer. I've clinicians we for got that be country ability They trial targeting you think TPIVXXX sites enrollment again this the right XX a Clinic, the time enroll To-date, this been [Moffitt] rate would time in ovarian is that in patients. interest clinical that a of sites amount at including Currently, our think they're engagement the think others.

Steve Brozak

that had going more And obviously and this during had into clinician that mentioned the you interest. detail, And X have call patient you back you programs. getting

at from potential you. with I'll and what seen in that the potential collaborators interested. biotech and with you them, got question all kind back collaboration also Let's site. is would component in on one forward so I've potentially How how potentially the Obviously you be this looking have last And something you? large of taking about technology going the you And has that see place? your interest pharma more Thank queue. working jump would any them would corporate or and one far see talk

Peter Hoang

you time is then immuno-oncology transaction time that spent the thing. I that. Well is in you perfect my collaborations. X a I’ll a another doing to background do Wall Street that there tell a know right less years strategic and XX same think strategic and doing absolutely. years I've Yes, than on

that haven’t readout the we what and an extraordinarily I our you Researchers a we is though first factor journal X with to Journal therapeutic publication step the in important Phase recognition we I that represents that look between That as the And measuring X.X. of even that I here was was some statistical long for what saw time XXX because and measured actually there XXth in clinical see date the care therapy. relaxed. of Cancer a vaccine. the tell at terms numbers free When patients time. laid. research, it's first XXX The these of got significance. between noise we actually an time think get surgery evidence our Phase X impact some it median time patient And When got patient was standard getting It’s is pleased we program the date that show that from progression the we of efficacy to our of patients Association What that you survival recruited data that progression enough result took could And published. patients they that the therapy. get think XXX the of those is percentile cancer we and to real the you time a which those that. that was received are days days. the surgery of time establishing clear know the extraordinarily has the in XXX trial were days a positive a survival that in fact free reach very American beginning is that And our in had data median know the Avastin I’d in patients there's

potentially our and phase received collected clinical not estimate least was but XXX these therapy. they days as received patients in but time you was that it our that much unfortunately days, the as in XX that surgery that trial, up time easily can X point Now, and the to data at

argue And that the a better conceivably is days. efficacy That our So ever the I very think in a standalone I the well has is that first signal than be it XXX signal of that that would significantly like I of vaccine. be seen could number may said as important efficacy vaccine in anyone cancer therapeutic.

really And But X to the the Phase that readout our patients. so lot extremely that partners. with important real the that had therapeutic meaningful was proof I of first results therapy result delivering we share attention we that corporate capture that opportunity think and from a think that have world is going it's to an potential is for

statistically going to with clinical we up some Now, from it And in standpoint the pushing middle evaluation the clinical think is to trials background for the a our kind today. is think evaluation we be an don't time given potential of are that forward where corporate result. for think is I is reality that catch development the significant to that optimal part I motivate business trial to in going I’ll more from stand take a going that and our generating that partners. these readout I time Coming you things tell there

will in receive that not have think I but that we short-term conversations it evaluation. that generate results that don’t best fruitful our for I can the we I optimal would the Look can necessarily think necessarily shareholders. but partner

shareholders be is generate engage will to partnering the in for negotiations. we we results where strongest that the that think extent I

comes X. that after from that think readout the I Phase the

Steve Brozak

question, was on a I administration. detailed as that answer more in of terms this don’t a reaction is mentioned, slight know there want question how Last you to

that? event what something related is see. Or adverse as is to administration that in we've or don't after intuitive well this like to anything want want see, it's the actually all something that the to but immune be case to you given site we that’s slight be immune would that's else Now system that how would recruited, given that, how response to say an fair robust it been conditioned say reaction

that? So that's And my how would last question? you describe

Peter Hoang

point, to-date you but trial trial tell dosing placebo-controlled I’ll over that a we’ve absolutely, this well Rick one have over and going I’m X number given a to about tell given dosed trial. to maybe efficacy give low. you response, it and we patients to TPIVXXX the site XXX and of ongoing and extraordinarily talking a kick at Phase the really related the that's XXX with you I'll Yes, that the dosed patients reaction that over fuller is

significant almost the of PARP that receives patient which it. to this in have every remember comes competition for that form have inhibitors, in primary vaccine You toxicities our

when And effect swelling injection most to so let to remember flu to where when common having here one effect an intradermal site. side is over you get side you shot what you case kick around which Rick got think reaction. have get an a about for -- you about injection But the you the broadly and profile, related that I dissimilar is not extreme it to effectively that, me redness the think that said is infusion talk

Dr. Richard Kenney

extent great or And in fact often responding been shows been by some site actually on set that and call some What between is as is medical we that thing fact cells, repeatedly rotate she inflammatory to well, as leg drug is all pain way. or her is have her dose, have that injection an very ulceration have which redness and seems on simply out of to to events. of have -- infiltration my developing reaction. job reactions it only be some of to-date the that to X, X done to now, immune sites arm got actually a the we’ve the two the working carefully know. almost to think as given was forearm it that be many bit future But limited fixed of that is of redness grade it's a the good at skin in patients bit of this we Grade is in this out doing patient you’ve vaccines, local and avoid we’re common as the immune was Grade adverse thing XXX site. the considered reflective the a to you’d to vaccine of an dosed. and patient, to had this, related you have had the very criteria fifth turns career In CTCA The that actually related either a I identify site getting to one possible was little my and a over look you very a with site the a I at in monitor and body the was either very to any skin, to

of an adverse considered, I so, that agree considered event, something And it’s the while something it's vaccine locally. yes, the that considered, also should is be I demonstrating affect

Operator

this to time. there look further And be at no questions

So, turn this the like to Peter over any closing our for I to session. remarks. would will conclude question-and-answer conference Hoang back

Peter Hoang

is an thank our the much. I absolutely of delivering, what all Mayo think of for I very employees all you and want fabulous again, shareholders, Once our Thank Clinic to quarter.

progress as getting X in of I programs we driving data improving our X forward quarter clinical made Phase all terms terms and of substantial the think major well last that Phase the our milestones, as to significant over meaningful clinic in very published. on deliver managed have we’ve operations, in clinical this of

with further the Going forward, occur very in looking of to to developments I’m Mayo the reporting negotiations U.S. to with Clinic. respect Department much back ongoing as you the Defense

to so of look quarter. by optimistic conjunction very U.S. I’m with the excited trial very the doing much. of as about largest forward I all again speaking prospect very, We’re you the potentially, you said forward Thank and trial from a Defense. Mayo clinical next to-date with Rick funding very Department our going third clinical possibility with and full in

Operator

now And the concluded. for has you disconnect. may and conference now Thank today’s presentation you attending

Marker Therapeutics (MRKR) 5 Apr 182017 Q4 Earnings call transcript